NE3107 Trial in Adults with Long COVID Symptoms
Phase 2
208
about 9 months
18–69
20 sites in CA, CO, CT +14
What this study is about
This trial is testing NE3107, a medication, to see if it helps treat neurological symptoms like brain fog and fatigue that can persist after a COVID-19 infection. Researchers will compare NE3107 to a placebo (a look-alike substance) to determine if NE3107 works to improve neurocognitive and fatigue symptoms of long COVID. Participants will take NE3107 or a placebo twice daily for 84 days, visit the clinic multiple times for checkups and tests, and have follow up phone calls.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take NE3107
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from Baseline in performance on the Cogstate Cognition battery
Secondary: Change from Baseline in DePaul Symptom Questionnaire (DSQ) Post-Exertional Malaise (PEM, Change from Baseline in PROMIS Cognitive Function Short Form 8a (SF-8a), Change from Baseline in PROMIS Fatigue Short Form 13a (SF-13a), Change from Baseline in PROMIS Sleep Disturbance Short Form 8a (SF-8a), Change from Baseline in SF-12 Health Survey (Physical and Mental Component Scores)